WESTMINSTER, Colo. --(BUSINESS WIRE)--Sep. 22, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid
WESTMINSTER, Colo. --(BUSINESS WIRE)--Aug. 31, 2026-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary
Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting Conference Call and Webcast today at 4:30pm ET DENVER --(BUSINESS WIRE)--Aug.
WESTMINSTER, Colo. --(BUSINESS WIRE)--Jul. 29, 2026-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary
WESTMINSTER, Colo. --(BUSINESS WIRE)--Jul. 16, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors,
Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share clinical experience and patient case examples WESTMINSTER, Colo. --(BUSINESS WIRE)--Jun.
Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader market penetration Published landmark, real-world PEDD ® Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure
Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance despite greater baseline clinical complexity WESTMINSTER, Colo.
WESTMINSTER, Colo. --(BUSINESS WIRE)--May 4, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid
Conference Call and Webcast Scheduled for Tuesday, May 12, 2026 at 4:30 PM WESTMINSTER, Colo. --(BUSINESS WIRE)--Apr. 28, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its